Lebrikizumab

Lebrikizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL-13
Clinical data
Trade namesEbglyss
Other namesMILR1444A, RG3637, TNX-650, lebrikizumab-lbkz
AHFS/Drugs.comMonograph
MedlinePlusa624064
License data
Pregnancy
category
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6434H9972N1700O2034S50
Molar mass145287.42 g·mol−1
 NY (what is this?)  (verify)

Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema).[7][8] It is an interleukin-13 antagonist.[7] It is given by subcutaneous injection.[7]

The most common side effects include injection site reactions, dry eye and conjunctivitis (redness and discomfort in the eye) including allergic conjunctivitis.[8]

Lebrikizumab was approved for medical use in the European Union in November 2023,[8] in Canada in June 2024,[5] and in the United States in September 2024.[10]

  1. ^ "Ebglyss (lebrikizumab)". Therapeutic Goods Administration (TGA). 23 June 2024. Retrieved 7 July 2024.
  2. ^ "Ebglyss (Eli Lilly Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Archived from the original on 7 July 2024. Retrieved 7 July 2024.
  3. ^ "Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Archived from the original on 10 June 2024. Retrieved 10 June 2024.
  4. ^ "Summary Basis of Decision for Ebglyss". Drug and Health Products Portal. 18 December 2024. Retrieved 25 January 2025.
  5. ^ a b "Ebglyss Product information". Health Canada. 24 June 2024. Archived from the original on 15 July 2024. Retrieved 15 July 2024.
  6. ^ "Regulatory Decision Summary for Ebglyss (lebrikizumab)". Drug and Health Products Portal. 24 June 2024. Retrieved 27 December 2024.
  7. ^ a b c d "Ebglyss- lebrikizumab-lbkz injection, solution". DailyMed. 19 September 2024. Archived from the original on 7 October 2024. Retrieved 5 October 2024.
  8. ^ a b c d "Ebglyss EPAR". European Medicines Agency (EMA). 21 November 2023. Archived from the original on 22 November 2023. Retrieved 22 November 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. ^ "Ebglyss Product information". Union Register of medicinal products. 17 November 2023. Archived from the original on 26 November 2023. Retrieved 11 December 2023.
  10. ^ "Drug Approval Package: Ebglyss". U.S. Food and Drug Administration (FDA). 15 October 2024. Retrieved 14 July 2025.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.